| Literature DB >> 31409420 |
Shalu Jain1, Kavitha Rajshekar2, Anjana Aggarwal2, Akshay Chauhan2, Vijay Kumar Gauba2,3.
Abstract
BACKGROUND: Cataract is the leading cause of blindness and low vision worldwide. Presently, cataract surgery is the only treatment for cataract and is very effective in restoring sight. In cataract surgery, the natural lens of the eye that becomes clouded is removed and replaced with an artificial intraocular lens. There are multiple techniques for removal of lens as well as many types of intraocular lenses available for implantation. For this reason, it becomes imperative to monitor the impact of different surgical techniques and different intraocular lenses on health-related quality of life (HRQoL) of the patients. This systematic review aims to evaluate HRQoL evidences on effects of different types of cataract surgeries and intraocular lenses on visual function and quality of life in age-related cataract patients.Entities:
Keywords: Cataract; Cost effectiveness; Economic evaluations; Health technology assessment; Health-related quality of life; Visual function
Mesh:
Year: 2019 PMID: 31409420 PMCID: PMC6693150 DOI: 10.1186/s13643-019-1113-6
Source DB: PubMed Journal: Syst Rev ISSN: 2046-4053
Preliminary data extraction table to be used for inclusion/exclusion of studies
| Serial No. | |
| Study ID | |
| Title of study | |
| Published in year | |
| Study design | |
| Patient population | |
| Intervention | |
| Comparator (If any) | |
| Outcome measures (e.g. visual acuity, QoL, VF) | |
| Instruments used | |
| Included/excluded | |
| Reason for exclusion |
Data extraction table to be used for included studies
| Category (study is related to surgical techniques, intraocular lenses, surgical complications or any other aspect of cataract) | |
| Study ID | |
| Title of the study | |
| Year of publication | |
| Country where the work is done | |
| Aim of the study | |
| Study settings | |
| Study design | |
| Randomisation method (If RCTα) | |
| Preference-based measures (generic/disease specific) | |
| Which instrument is used | |
| Sample size | |
| Age criteria for patient recruitment | |
| Patient recruitment details | |
| Follow up details | |
| Tariff details | |
| Modelling details | |
| Statistical tests used | |
| Cost-effectiveness analysis (e.g, ICERβ, NHBγ) | |
| Average age of patients | |
Visual function scores Pre-surgery Post-Surgery | |
Quality of life scores Pre-surgery Post-surgery | |
| Results | |
| Conclusion | |
| Reviewer’s remarks |
αRandomised Controlled trials, β- Incremental cost effectiveness ratio, γ- Net Heath Benefit
βIncremental cost-effectiveness ratio
γNet heath benefit
Quality assessment checklist used for included studies (modified from Ara et al.) [24]
| Criteria | Consideration |
|---|---|
| Criteria 1. Relevance of the study | |
| Relevant population | How closely do the patient characteristics in the study match to the patient population we have described in our inclusion criteria (PICO) |
| Relevant health states | Timing of data collection, e.g. pre-surgery, post-surgery, follow-up intervals. The use of any medications that is likely to have an independent effect on HSUVs (either detrimental or beneficial) |
| Criteria 2. Quality assessment | |
| Sample size | This was not considered as exclusion criteria, but the precision of the estimate was assessed |
| Response rates to the measure used | Are response rates reported and if so, are the rates likely to be a threat to the validity of the estimated HSUVs for the health states? |
| Loss to follow-up | How large is the loss to follow-up and are these likely to threaten the validity of the estimates? |
| Missing data | What are the levels of missing data and how are they dealt with? Are there details on the causes of the missing data? Again, could this threaten the validity of the estimates? |
| Criteria 3. Utility values are measured and valued appropriately | |
| Appropriate use of valuation method | If valuation methods are used (TTO, SG, DCE, VAS) they are used appropriately? Does the valuation method provide preference based values anchored at 1 as equivalent to full health and 0 as equivalent to dead? Are adequate details of the valuation method provided to allow judgement on appropriateness? |
| Appropriate use of GPMB | Are adequate details of the PBM method provided (e.g. details given on the version used, the social tariff applied) Was the GPBM delivered as intended? (e.g. wording and response options not changed) Is the measure used for the group it was intended (e.g. is an adult GPBM being used for children? Is EQ-5D-Y used with the adult tariff?) |
| Appropriate health-state description (vignette) | If a health state is valued using a vignette, can the accuracy of the vignette be established? e.g. the process by which it was derived is described |